Drug intelligence / Profile preview

ACC077

Development stage: Preclinical
Lead developer: AIDEA PHARMA
Modality: Small Molecules
Administration: Oral

Overview

ACC077 is an investigational, oral long-acting small molecule HIV-1 capsid inhibitor being developed by Jiangsu Aidea Pharma for HIV pre-exposure prophylaxis (PrEP). It targets the HIV-1 capsid protein (CA) and acts by interfering with multiple stages of the viral life cycle, including capsid-mediated nuclear uptake of the pre-integration complex, viral particle production, and proper capsid core assembly, thereby rendering the virus replication-incompetent. ACC077 is designed as a once-monthly oral tablet to improve medication adherence and provide a convenient home-based prevention option for high-risk populations. It is currently in preclinical development.

Other names: ACC077 tabletACC-077 tabletACC 077 tabletACC077片

Targets

p24 (HIV-1 capsid protein p24)

Beyond the preview

Go deeper on ACC077.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ACC077.

Explore the full profile